Stifel Financial Corp Takes $43,000 Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Stifel Financial Corp purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 10,265 shares of the company’s stock, valued at approximately $43,000.

A number of other institutional investors and hedge funds have also bought and sold shares of SANA. FMR LLC boosted its holdings in Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after acquiring an additional 4,438,949 shares during the last quarter. Integral Health Asset Management LLC boosted its holdings in Sana Biotechnology by 22.4% during the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after purchasing an additional 220,000 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Sana Biotechnology by 11.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock worth $4,359,000 after purchasing an additional 105,382 shares in the last quarter. Squarepoint Ops LLC increased its stake in Sana Biotechnology by 318.8% in the 2nd quarter. Squarepoint Ops LLC now owns 126,572 shares of the company’s stock valued at $691,000 after buying an additional 96,348 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Sana Biotechnology by 26.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock worth $2,357,000 after buying an additional 90,423 shares in the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SANA has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Sana Biotechnology in a report on Wednesday, November 27th. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th.

Sana Biotechnology Price Performance

SANA opened at $1.61 on Tuesday. Sana Biotechnology, Inc. has a twelve month low of $1.52 and a twelve month high of $12.00. The company’s 50-day moving average price is $2.68 and its two-hundred day moving average price is $4.28. The stock has a market cap of $359.46 million, a price-to-earnings ratio of -1.15 and a beta of 1.33.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. As a group, sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.